Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma. Sepranolone is a neurosteroid being developed as a potential treatment for ...

The directors of Asarina Pharma have abandoned a search for a partner for Tourette's syndrome treatment sepranolone, saying they have no choice but to liquidate the company. Just over a year ago ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...